Accueil   Diary - News   All news Imaxio sells Trolovol®

Imaxio sells Trolovol®

Imaxio sells Trolovol® (D-penicillamine) to focus on vaccines

 

This divestment enables Imaxio to focus exclusively on the development of its pipeline of vaccine candidates based on the IMX313 technology, and on the commercialisation of the vaccine Spirolept®

 

Read the press release

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree